The Filing Desk

Nasus Pharma vs Supernus

Nasus Pharma NSRX · Supernus SUPN · Pharmaceuticals

Supernus reported revenue of $1.2 billion in fiscal 2025, about the same as Nasus Pharma's $1.2 billion in fiscal 2025. Nasus Pharma had an operating margin of -0.4%, against 21.1% at Supernus. Free cash flow was −$5 million at Nasus Pharma and −$93 million at Supernus.

Side by side

Nasus PharmaSupernus
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.2B$1.2B
Revenue growth—4.3%
Revenue growth a year, last 5 years——
Gross margin—80.2%
Operating margin−0.4%21.1%
Net margin−0.5%16.9%
Free cash flow−$5M−$93M
Free cash flow margin−0.4%−7.5%
Return on capital——
Net debt to EBITDA—0.5x
Dividends and buybacks$0M$11M
Change in diluted share count14.0%−3.8%
Last close$2.55$28.35
P/E at the last close—7.9×
Insider trades, last 12 monthsbought $61,809, sold $0bought $229,274, sold $2.8 million
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Nasus PharmaSupernus
Operating margin
Percent of revenue
Nasus PharmaSupernus
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nasus PharmaSupernus

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nasus Pharma and Supernus pages.